Safe Management of People With Type 1 Diabetes and EAting Disorders studY (STEADY-II)
Primary Purpose
Diabetes Mellitus, Type 1, Eating Disorders
Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
STEADY intervention
Sponsored by
About this trial
This is an interventional other trial for Diabetes Mellitus, Type 1 focused on measuring Type 1 diabetes, Eating disorder, Diabulimia, EDNOS
Eligibility Criteria
Inclusion Criteria:
- Adults (≥18 years);
- Diagnosis of type 1 diabetes mellitus for at least 6 months;
- Current disordered eating: defined as fear of insulin as weight gaining, avoidance/ restriction of insulin to control weight, food restriction, binge eating, any additional disordered eating behaviour as described by the 5th revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), or 11th Revision of the International Classification of Diseases (ICD-11); AND/OR score of 15 on EDE-QS, AND/OR a score of 20 on the DEPS-R.
- Prepared to take part in a cognitive-behavioural therapy approach behaviour change strategy plus diabetes education intervention (with up to 12 sessions) with a varying proportion of face-to-face and virtual delivery mode;
- Prepared to take part in the control group - treatment as usual (TAU)
- Prepared to attend physical and mental health check-up at baseline and at the end of the intervention (control arm and intervention arm) face-to-face;
- Currently under the care of a diabetes specialist team (as this study does not replace usual diabetes care);
- Confirms availability to attend all sessions as part of the intervention (with the option of rescheduling sessions when necessary. Therapy sessions may be in person or via videoconference);
- Investigator has confidence that the participant is able to fulfill all of the trial protocol requirements;
- Participant has capacity to consent to the study. This is assessed by ability to explain information about their involvement in the study.
Exclusion Criteria:
- HbA1c >15%/ 140.4 mmol/mol;
- More than 2 admissions for DKA in the past 12 months;
- More than 2 SH episodes (defined as needing 3rd party assistance) in the past 12 months due to insulin omission (not if triggered by infection or canula failure);
- Severe mental illness, including severe depression with suicidal ideation, psychosis, emotionally unstable personality disorder requiring more intensive psychiatric treatment, substance problem use and dependence. (Potential participants with more severe mental illness are unlikely to benefit from a CBT based approach, therefore will be excluded to not delay their treatment. Investigators will use their clinical judgement, in agreement with the trial team. Mental health assessment by a psychiatrist is part of the baseline visit.);
- Body mass index below 15kg/m2 or above 40kg/m2;
- Significant cognitive impairment, e.g. dementia, learning disability;
- Unable to speak/hear/understand/read/write in English;
- Unable to give written informed consent;
- Pregnant or planning pregnancy;
- Advanced diabetes complications (end stage renal failure, registered blind, limb amputation);
- Uncontrollable electrolyte disturbance, low blood pressure (<100/60mmHg), ECG abnormalities related to malnutrition (QTc-prolongation) or other physical conditions requiring inpatient treatment.
Sites / Locations
- King's College HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
STEADY intervention group
Treatment as usual group (control)
Arm Description
Outcomes
Primary Outcome Measures
HbA1c
HbA1c measured in mmol/mol
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05140564
Brief Title
Safe Management of People With Type 1 Diabetes and EAting Disorders studY
Acronym
STEADY-II
Official Title
Safe Management of People With Type 1 Diabetes and EAting Disorders studY - Phase II
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 18, 2022 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
There is currently no effective intervention for type 1 diabetes and eating disorders. The main objective of STEADY Stage 2 is to test the feasibility of the newly developed STEADY intervention.
STEADY was co-designed by using Experience Based Co-Design methodology and other qualitative methods (focus groups, interviews).
These findings informed the development of a T1DM cognitive behaviour therapy (CBT) manual. The intervention will now be tested in a feasibility Randomised Controlled Trial (RCT) in adults with type 1 diabetes and eating disorders and compared with usual clinical care. If STEADY is feasible, this may provide an effective intervention for this population.
This study will take place at King's College London. Participants will remain in the study for 6 months, with a 12-month extended observation period. The study is expected to end in February 2023.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1, Eating Disorders
Keywords
Type 1 diabetes, Eating disorder, Diabulimia, EDNOS
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
STEADY intervention group
Arm Type
Experimental
Arm Title
Treatment as usual group (control)
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
STEADY intervention
Intervention Description
STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
Primary Outcome Measure Information:
Title
HbA1c
Description
HbA1c measured in mmol/mol
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults (≥18 years);
Diagnosis of type 1 diabetes mellitus for at least 6 months;
Current disordered eating: defined as fear of insulin as weight gaining, avoidance/ restriction of insulin to control weight, food restriction, binge eating, any additional disordered eating behaviour as described by the 5th revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), or 11th Revision of the International Classification of Diseases (ICD-11); AND/OR score of 15 on EDE-QS, AND/OR a score of 20 on the DEPS-R.
Prepared to take part in a cognitive-behavioural therapy approach behaviour change strategy plus diabetes education intervention (with up to 12 sessions) with a varying proportion of face-to-face and virtual delivery mode;
Prepared to take part in the control group - treatment as usual (TAU)
Prepared to attend physical and mental health check-up at baseline and at the end of the intervention (control arm and intervention arm) face-to-face;
Currently under the care of a diabetes specialist team (as this study does not replace usual diabetes care);
Confirms availability to attend all sessions as part of the intervention (with the option of rescheduling sessions when necessary. Therapy sessions may be in person or via videoconference);
Investigator has confidence that the participant is able to fulfill all of the trial protocol requirements;
Participant has capacity to consent to the study. This is assessed by ability to explain information about their involvement in the study.
Exclusion Criteria:
HbA1c >15%/ 140.4 mmol/mol;
More than 2 admissions for DKA in the past 12 months;
More than 2 SH episodes (defined as needing 3rd party assistance) in the past 12 months due to insulin omission (not if triggered by infection or canula failure);
Severe mental illness, including severe depression with suicidal ideation, psychosis, emotionally unstable personality disorder requiring more intensive psychiatric treatment, substance problem use and dependence. (Potential participants with more severe mental illness are unlikely to benefit from a CBT based approach, therefore will be excluded to not delay their treatment. Investigators will use their clinical judgement, in agreement with the trial team. Mental health assessment by a psychiatrist is part of the baseline visit.);
Body mass index below 15kg/m2 or above 40kg/m2;
Significant cognitive impairment, e.g. dementia, learning disability;
Unable to speak/hear/understand/read/write in English;
Unable to give written informed consent;
Pregnant or planning pregnancy;
Advanced diabetes complications (end stage renal failure, registered blind, limb amputation);
Uncontrollable electrolyte disturbance, low blood pressure (<100/60mmHg), ECG abnormalities related to malnutrition (QTc-prolongation) or other physical conditions requiring inpatient treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marietta Stadler, Dr
Phone
02078485664
Email
marietta.stadler@kcl.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Natalie Zaremba, Ms
Email
natalie.zaremba@kcl.ac.uk
Facility Information:
Facility Name
King's College Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marietta Stadler
12. IPD Sharing Statement
Learn more about this trial
Safe Management of People With Type 1 Diabetes and EAting Disorders studY
We'll reach out to this number within 24 hrs